Biofrontera is a pharmaceuticals business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 149 staff and has a trailing 12-month revenue of around $28 million.
Our top picks for where to buy Biofrontera stock
How to buy Biofrontera stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BFRA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Biofrontera stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Biofrontera stock price (NASDAQ: BFRA)
Use our graph to track the performance of BFRA stocks over time.Biofrontera shares at a glance
Latest market close | $1.94 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $2.89 |
200-day moving average | $4.65 |
Wall St. target price | $8.50 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.61 |
Is it a good time to buy Biofrontera stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biofrontera price performance over time
Historical closes compared with the close of $1.94 from 2022-05-06
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-03) | N/A |
---|---|
2 years (2022-09-03) | N/A |
3 years (2021-09-07) | 5.8 |
5 years (2019-09-06) | 14.342 |
Is Biofrontera stock undervalued or overvalued?
Valuing Biofrontera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biofrontera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biofrontera's EBITDA
Biofrontera's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 million.
The EBITDA is a measure of a Biofrontera's overall financial performance and is widely used to measure a its profitability.
Biofrontera financials
Revenue TTM | $28 million |
---|---|
Gross profit TTM | $26.8 million |
Return on assets TTM | -10.51% |
Return on equity TTM | -124.08% |
Profit margin | -55.98% |
Book value | $0.76 |
Market Capitalization | $75.7 million |
TTM: trailing 12 months
Biofrontera share dividends
We're not expecting Biofrontera to pay a dividend over the next 12 months.
Biofrontera share price volatility
Over the last 12 months, Biofrontera's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.548. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Biofrontera overview
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co.
Frequently asked questions
nullWhat percentage of Biofrontera is owned by institutions?
Currently 3.004% of Biofrontera shares are held by institutions. How many people work for Biofrontera?
Latest data suggests 149 work at Biofrontera. When does the fiscal year end for Biofrontera?
Biofrontera's fiscal year ends in December. Where is Biofrontera based?
Biofrontera's address is: Hemmelrather Weg 201, Leverkusen, Germany, 51377 What is Biofrontera's ISIN number?
Biofrontera's international securities identification number is: US09075G1058 What is Biofrontera's CUSIP number?
Biofrontera's Committee on Uniform Securities Identification Procedures number is: 09075G105
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question